Table 3.
Univariate and Multivariate Analysis of Risk Factors for Overall Survival and Progression-Free Survival
| Variables | Overall Survival | Progression-Free Survival | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis | |||||||||
| HR | 95% CI | P | HR | 95% CI | P value | HR | 95% CI | P | HR | 95% CI | P | |
| Age (years), (≤/>50) | 0.767 | 0.495–1.190 | 0.237 | 0.736 | 0.533–1.016 | 0.062 | ||||||
| Gender, (female/male) | 0.889 | 0.469–1.684 | 0.719 | 0.935 | 0.570–1.532 | 0.788 | ||||||
| Hepatitis B, (no/yes) | 1.454 | 0.669–3.159 | 0.334 | 0.919 | 0.538–1.570 | 0.757 | ||||||
| HBV-DNA, (≤/>10E3) | 1.854 | 1.152–2.984 | 0.011 | 1.271 | 0.909–1.778 | 0.161 | ||||||
| Liver cirrhosis (no/yes) | 1.032 | 0.656–1.624 | 0.892 | 0.790 | 0.568–1.099 | 0.162 | ||||||
| NLR, (≤/>3) | 0.991 | 0.638–1.539 | 0.967 | 1.030 | 0.746–1.423 | 0.855 | ||||||
| PLT (10E9/L), (≤/>100) | 1.092 | 0.441–2.707 | 0.849 | 1.500 | 0.735–3.061 | 0.265 | ||||||
| ALT (U/L), (≤/>50) | 1.192 | 0.769–1.849 | 0.433 | 1.005 | 0.728–1.388 | 0.975 | ||||||
| AST(U/L), (≤/>50) | 2.283 | 1.403–3.713 | 0.001 | 2.210 | 1.345–3.630 | 0.002 | 1.133 | 0.816–1.575 | 0.456 | |||
| AFP (ng/mL), (≤/>400) | 2.149 | 1.322–3.492 | 0.002 | 1.920 | 1.158–3.182 | 0.011 | 1.759 | 1.252–2.471 | 0.001 | 1.753 | 1.248–2.463 | 0.001 |
| DCP, (mAU/mL), (≤/>400) | 2.271 | 1.165–4.427 | 0.016 | 1.439 | 0.942–2.200 | 0.093 | ||||||
| Child–Pugh score (5/6) | 1.502 | 0.887–2.545 | 0.130 | 1.102 | 0.716–1.696 | 0.659 | ||||||
| BCLC (B/C) | 2.174 | 1.302–3.631 | 0.003 | 1.311 | 0.932–1.845 | 0.120 | ||||||
| Tumor size (cm), (≤/>10) | 1.785 | 1.136–2.804 | 0.012 | 1.257 | 0.907–1.742 | 0.169 | ||||||
| Tumor number (1/>1) | 1.239 | 0.695–2.209 | 0.467 | 1.168 | 0.778–1.754 | 0.455 | ||||||
| Tumor distribution (uni-/bi-lobar) | 1.156 | 0.743–1.798 | 0.519 | 1.200 | 0.867–1.660 | 0.271 | ||||||
| Tumor thrombusa | ||||||||||||
| Absent | – | – | – | – | – | – | ||||||
| Vp 1–3 | 1.607 | 0.969–2.666 | 0.066 | 1.433 | 0.848–2.421 | 0.179 | 1.200 | 0.847–1.699 | 0.305 | |||
| Vp 4 | 3.087 | 1.641–5.807 | <0.001 | 2.627 | 1.392–4.957 | 0.003 | 1.243 | 0.748–2.067 | 0.401 | |||
| Extrahepatic metastasis (no/yes) | 2.023 | 1.258–3.255 | 0.004 | 1.658 | 1.148–2.397 | 0.007 | ||||||
| Anti-PD-1 combined (no/yes) | 0.557 | 0.343–0.907 | 0.018 | 0.518 | 0.314–0.854 | 0.010 | 0.615 | 0.433–0.872 | 0.006 | 0.617 | 0.435–0.876 | 0.007 |
Note: aTumor thrombus classification according to management of hepatocellular carcinoma in Japan.
Abbreviations: PD-1, programmed death protein 1; HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; NLR, neutrophil–lymphocyte ratio; PLT, blood platelet; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AFP, alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin; BCLC, Barcelona Clinic Liver Cancer.